Profile data is unavailable for this security.
About the company
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company’s focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical development for the therapeutic delivery of inhaled nitric oxide. It is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. The Company’s subsidiaries include Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc.
- Revenue in USD (TTM)5.64m
- Net income in USD-9.25m
- Incorporated2013
- Employees18.00
- LocationBellerophon Therapeutics Inc184 Liberty Corner Road, Suite 302WARREN 07059United StatesUSA
- Phone+1 (908) 574-4770
- Fax+1 (302) 636-5454
- Websitehttp://www.bellerophon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emo Capital Corp | -100.00bn | -100.00bn | 639.85k | 0.00 | -- | -- | -- | -- | -- | -- | -- | -0.0017 | -- | -- | -- | -- | -- | -7,495.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -138.44 | -- | -- | -- |
| International Stem Cell Corp | 7.83m | -327.00k | 644.35k | 29.00 | -- | -- | -- | 0.0823 | -0.0409 | -0.0409 | 0.9785 | 0.0045 | 1.46 | 2.53 | 11.87 | 270,069.00 | -5.81 | -29.22 | -68.13 | -73.82 | 58.58 | 59.49 | -3.97 | -21.01 | 0.4672 | -6.06 | 0.9898 | -- | -4.78 | -6.82 | 60.42 | -- | -34.45 | -- |
| Capstone Holding Corp | 0.00 | -358.00k | 646.20k | 2.00 | -- | -- | -- | -- | -6.58 | -38.12 | 0.00 | -60.70 | 0.00 | -- | -- | -- | -113.46 | 141.94 | -199.60 | 173.06 | -- | -- | -- | -- | -- | -2.92 | -- | -- | -- | -- | 52.46 | -- | -- | -- |
| Bespoke Extracts Inc | 785.45k | -1.48m | 647.74k | 10.00 | -- | -- | -- | 0.8247 | -0.1458 | -0.1458 | 0.0774 | -0.1696 | 2.06 | 55.99 | 34.73 | 78,545.00 | -388.21 | -- | -- | -- | 43.69 | -- | -188.79 | -- | 0.0612 | -135.42 | -- | -- | 22,933.72 | -- | 63.98 | -- | -- | -- |
| Scisparc Ltd | 0.00 | -6.96m | 658.85k | 3.00 | -- | 27.05 | -- | -- | -1.22 | -1.51 | 0.00 | 0.0344 | 0.00 | -- | -- | 0.00 | -92.51 | -69.39 | -152.41 | -111.07 | -- | -- | -- | -527.17 | -- | -- | 0.9371 | -- | 113.73 | -- | -97.61 | -- | -- | -- |
| CNS Pharmaceuticals Inc | 0.00 | -17.46m | 661.34k | 3.00 | -- | -- | -- | -- | -179.17 | -179.17 | 0.00 | -20.76 | 0.00 | -- | -- | 0.00 | -384.86 | -132.47 | -- | -185.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.42 | -- | -- | -- |
| Sativus Tech Corp | 0.00 | -68.00k | 695.57k | -- | -- | -- | -- | -- | -0.0483 | -0.0483 | 0.00 | -0.5238 | 0.00 | -- | -- | -- | -18.83 | 25.48 | -- | -- | -- | -- | -- | -- | -- | -- | 5.41 | -- | -- | -- | 78.78 | -- | -- | -- |
| GlobeStar Therapeutics Corp | 0.00 | -1.98m | 697.75k | -- | -- | -- | -- | -- | -0.0023 | -0.0023 | 0.00 | -0.0015 | 0.00 | -- | -- | -- | -38,103.72 | -4,657.88 | -- | -- | -- | -7,790.20 | -- | -2,834,410.00 | -- | -21.00 | -- | -- | -- | -- | -31.01 | -- | -- | -- |
| Himalaya Technologies Inc | 0.00 | -629.85k | 762.40k | 2.00 | -- | -- | -- | -- | -0.003 | -0.003 | 0.00 | -0.002 | 0.00 | -- | -- | -- | -270.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -193.23 | -- | -- | -- |
| Comera Life Sciences Holdings Inc | 1.00m | -9.35m | 768.44k | 12.00 | -- | -- | -- | 0.7681 | -0.4901 | -0.4901 | 0.0512 | 0.0033 | 0.2498 | -- | 5.08 | 83,367.50 | -224.98 | -- | -1,094.30 | -- | 73.52 | -- | -900.55 | -- | -- | -- | 0.00 | -- | 97.95 | -- | -237.10 | -- | -- | -- |
| Bellerophon Therapeutics Inc | 5.64m | -9.25m | 776.77k | 18.00 | -- | 0.2086 | -- | 0.1377 | -0.8353 | -0.8353 | 0.5054 | 0.3044 | 0.6414 | -- | -- | 313,333.30 | -105.23 | -55.57 | -165.94 | -77.33 | -- | -- | -164.06 | -- | -- | -- | 0.00 | -- | -- | -- | -11.69 | -- | -- | -- |
| Evofem Biosciences Inc | 16.01m | 47.49m | 806.79k | 37.00 | 0.0014 | -- | 0.0169 | 0.0504 | -5.92 | -5.92 | 0.0826 | -1.36 | 0.935 | 1.72 | 2.73 | 432,756.80 | 295.02 | -211.64 | -- | -- | 63.65 | -- | 315.54 | -1,031.55 | 0.0757 | -2.91 | -- | -- | 8.20 | -- | 164.08 | -- | -10.59 | -- |
| GRI Bio Inc | 0.00 | -12.77m | 860.58k | 4.00 | -- | 0.2605 | -- | -- | -26.90 | -26.90 | 0.00 | 0.8753 | 0.00 | -- | -- | 0.00 | -382.23 | -192.93 | -869.57 | -353.99 | -- | -- | -- | -37,650.49 | -- | -16.80 | 0.00 | -- | -- | -- | -85.61 | -- | 29.46 | -- |
| Neutra Corp | 17.40k | -474.98k | 875.37k | -- | -- | -- | -- | 50.31 | -0.0002 | -0.0002 | 0.00001 | -0.0003 | 0.2786 | 0.4126 | -- | -- | -758.75 | -682.94 | -- | -- | 46.15 | -- | -2,723.22 | -2,758.85 | 0.0009 | -14.06 | -- | -- | -26.09 | -- | 22.28 | -- | -- | -- |
| Yield10 Bioscience Inc | 300.00k | -13.15m | 912.42k | 29.00 | -- | -- | -- | 3.04 | -146.30 | -146.30 | 1.06 | -123.90 | 0.0627 | -- | -- | 10,344.83 | -274.51 | -91.26 | -2,396.54 | -108.09 | -- | -- | -4,381.67 | -2,279.74 | -- | -- | -- | -- | -86.67 | -35.94 | -6.55 | -- | 1.84 | -- |
Data as of Jun 14 2024. Currency figures normalised to Bellerophon Therapeutics Inc's reporting currency: US Dollar USD
8.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Lepercq, de Neuflize Asset Management LLCas of 18 Dec 2023 | 1.03m | 8.39% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 4.52k | 0.04% |
| Janus Henderson Investors US LLCas of 30 Jun 2023 | 0.00 | 0.00% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 31 Mar 2024 | 0.00 | 0.00% |
| Puissance Capital Management LPas of 17 Oct 2023 | 0.00 | 0.00% |
| NFS Netfonds Financial Service GmbHas of 30 Sep 2023 | 0.00 | 0.00% |
More ▼
Data from 17 Oct 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
